ABSTRACT
INTRODUCTION
Brain cancer is a common cancer that affects more than 700,000 people in the US every year. Of these brain tumors, 80% are benign and 20% are malignant. More than any other cancer, brain cancers can have lasting life-altering impacts on a patient's life. This is because brain cancers, including benign tumors, can interfere with portions of the brain responsible for viral body functions including speech, motor functions etc.
The average survival rate for malignant brain tumor patients is only 33.8% in men, and 36.4% in women. The survival rate for the most common malignant brain tumorGlioblastoma (GBM) is only 5.5% 1,2 .
A total of 130 sub types of brain cancers have been discovered. Some relevant to this dataset are described here. Most common primary brain tumor is called Meningioma. These rise in the meninges (brain lining), and mostly occur in the 70s or 80s. These are typically slow growing, and can be of tumor grade 1, 2, or 3. Astrocytoma are the cancer of the cerebrum, and can be of any tumor grade. High grade (grade 4) Astrocytoma is called Glioblastomas (GBM). Oligodendroglioma are cancer in the cells that make the covering that protects nerves. These are also typically slow growing, and can be of tumor grade 1, 2, or 3. For most brain tumor types, surgery and radiation remain the standard of care. There are only four approved drugs for brain tumors, and little has changed over the last 30 years 2 .
All these facts mentioned above are related to primary brain tumors. Secondary brain tumors are tumors that start elsewhere in the body and metastasize to the brain. Approximately 80% of cancers are known to metastasize in the brain 2 .
Brain tumors are known to have the highest cost of care for any cancer group 2 . This combined with limited treatment options makes brain cancers a deadly disease. It is hence imperative to improve the prognosis and treatment of this cancer group.
In recent years, immunotherapy has shown much promise in the treatment of various cancers. The microenvironment of the normal brain and early stage tumors is immunosuppressive due to the blood-brain barrier (BBB). The central nervous system (CNS) is known to be 'immune privileged' due to the BBB, which limits infiltration of molecules and helps regulation of immune cells normal circumstance 3 . However, this viewpoint of immune privilege has been revised. The antigens derived from CNS have been shown to induce immune response. In cancer, the BBB often gets compromised resulting in more infiltration of immune cells 3, 4 .
In this analysis, we explore the dynamic changes in the expression of immune cells in the RNA of brain cancer patients. We used gene expression data from one of the largest brain cancer collections -the REMBRANDT project (REpository for Molecular BRAin Neoplasia DaTa) project that includes 671 patients 5, 6 . We applied virtual flow cytometry tools CIBERSORT 7 and xCell 8 to estimate the abundance of the immune cells in the RNA of these samples. We examine the immune cell landscape in this dataset and compared with that of the TCGA brain cancer collection, which includes 511 patients with Lower Grade Glioma (TCGA-LGG) and 156 patients with Glioblastoma (TCGA-GBM). We also discuss how well the results align with published literature, and how this computational analysis can help better understand how immune cells affect clinical outcome and survival in brain cancer patients
DATA
The dataset used in this analysis is called the REMBRANDT dataset (REpository for Molecular BRAin Neoplasia DaTa). It is a large brain cancer cohort, that includes 671 patients collected from 14 contributing institutions from 2004-2006 5, 6 . The project won the Service to America Award in 2005 9 . Madhavan et al 6 demonstrated the power of the data portal through several case studies.
The dataset includes a total of 671 patients with clinical data, of which 541 had gene expression data, and 507 patients had undergone SNP chip profiling. 263 patients had information about segment level copy number data. 220 patients had both gene expression and copy number data. Such combined datasets would provide researchers with a unique opportunity to conduct integrative analysis of gene expression and copy number changes in patients alongside clinical outcomes (overall survival).
For this analysis, we wanted to compare the immune infiltrates between the disease subgroups. 
METHODS
We used the REMBRANDT dataset to explore the dynamic changes in the expression of immune cells. We first applied virtual flow cytometry tools CIBERSORT 7 and xCell 8 on the processed gene expression data to estimate the abundance of the immune cells in the RNA of these samples. The raw gene expression data in the form of '.CEL' files, were initially processed according to the instructions of the CIBERSORT tool.
The estimated immune cells output was visualized using stacked bar graph and box plots. This allowed a visual comparison of the immune cell landscape of this dataset with that of the TCGA brain cancer collection and other public datasets. Gentles et al 7 , the creators of the CIBERSORT tool, applied their tool to the TCGA cancer collection that included brain cancers and other public datasets (https://precog.stanford.edu/iPRECOG.php) 7 .
We then used the estimated immune cells output to compare various disease subgroups. We focused on the comparison between Astrocytoma (Astro), Glioblastoma and Oligodendroglioma (Oligo). We used non parametric Wilcoxin Test 10 to compare each of these two groups. The results were in the form of differentially changed immune cell types.
We also compared these three groups in terms of copy number data, which is the form of chromosome instability index (CINdex). In Gusev et al 5 , we described the processing steps for this data conversion which was done using the CINdex Bioconductor package 11 . The CINdex package uses the segment level data to calculate the genomic instability in terms of copy number gains and losses separately at the chromosome and cytoband level. The genomic instability across a chromosome offers a global view (referred to as Chromosome CIN), and the genomic instability across cytobands regions provides higher resolution (referred to as Cytobands CIN) view of instability. This allows assessing the impacts of copy number alternations on various biological events or clinical outcomes by studying the association of CIN indices with those events. Each of these analyses in G-DOC was done on all patients that had data available.
This comparison of the disease sub-groups using the CINdex data was performed using the G-DOC platform using a student's T test 12 . The results were in the form of differentially changed cytobands. We then used the CINdex Bioconductor package to find out which genes were present in these differentially changed cytoband regions. After we obtained the gene list, we performed system biology analysis to find out which biological processes were implicated (using R package EnrichR). Figure 1 shows the workflow diagram Figure 2A shows the immune cell landscape of the Rembrandt data using estimation from CIBERSORT. Figure 2B is from Gentles et al (2015) 7 showing immune cell landscape of the TCGA data collection (also using CIBERSORT). Figure 2C shows immune cell landscape of various public datasets (also using CIBERSORT), taken from iPRECOG 7 . Figure 2C shows immune cell landscape of various public datasets (also using CIBERSORT), taken from iPRECOG website
RESULTS

Analysis of immune cell landscape based on gene expression data
We also visualized the estimated immune cell types using box plots. Figure 3A shows the box plot of immune cells estimates from the tool CIBERSORT, while Figure 3B shows immune cell fractions estimated by the tool xCell. 
Analysis of immune response landscape based on copy number data
Comparing groups using cytoband level CIN data
We also compared these three groups in terms of copy number data, which is the form of chromosome instability index (CINdex) using Students T-test using G-DOC. The differentially changed cytobands have been summarized in Table 3 and visualized as a circus plot (Figure 4 Once we obtained the genes located in the differentially changed cytoband regions, we performed system biology analysis. The biological processes enriched in Gene Onotology are shown in Table 4 . 
DISCUSSION
From Figure 2 , we can see that majority of the immune cells within brain tumors are macrophages. In Figure 3A , we can see that some cell types show immune suppression in higher grade cancer subtype compared to lower grade sub-types (e.g. B cells memory, T cells CD8, Dendritic cells resting, Mast cells activated). In the same figure, we can see that other cells types are upregulated in higher grade disease sub-types (E.g. Macrophages M2, CD4 memory resting, B cells memory naïve).
From the circus plot (Figure 4) , we can easily spot the 1p/19q co-deletion in the group comparisons where Oligodendroglioma patient are involved. The 1/19q co-deletion has been used as a prognostic and predictive biomarker in Oligodendrogliomas [13] [14] [15] .
In our results, Natural Killer (NK) cells were activated in GBM when compared to Oligo in both CIBERSORT and Copy number results. This is consistent with literature. It is known that the function of NK cells is often affected in brain cancer patients. One such example is TGFB down-regulates the expression of NKG2D activating receptor on NK cells in GBM patients. Decreased numbers of NK cells were observed in the blood of GBM patients post radiation treatment 16 .
In our data, we saw that GBM patients had high T cells CD4 memory resting, and lowest CD8 T cells ( Figure 3A ). According to published literature, GBM patients a high level of CD4+ TILs combined with low CD8+ TILs was associated with unfavorable prognosis 17 .
Tumor aneuploidy (somatic copy number alterations) correlates with markers of immune evasion and with reduced response to immunotherapy 18 . Highly aneuploid tumors show reduced expression of CD8+ T cells. In our results, we see reduced T cells CD8 in GBM (Figure 3) . Hence results are consistent with literature.
Also, tumor associated macrophages (TAMs) within the brain tend to be protumorigenic and accumulate with higher tumor grade. TAMs have been implicated in brain tumor angiogenesis and resistance to anti-angiogenic therapies 4 .
It is important to note that copy number results from our analysis suggest similar pattern of immune cell response as Cibersort results. We found that the majority of categories of biological processes that are affected by cytoband level instability are mostly related to the processes involving the same categories of immune cells such asL B cells proliferation and differentiation, T cells activation, Natural Killer Cells activation etc.. These findings indicate that copy number changes in brain tumors playing important role in affecting immune cell activity in brain tumor microenvironment.
Tumor microenvironment in brain cancers
The microenvironment of the normal brain & early-stage brain tumors is generally immunosuppressive due to the blood-brain barrier (BBB). Immune privilege qualities of the Central Nervous System (CNS) have been attributed to the BBB which limits transit of molecules and helps regulate lymphocyte tracking under normal circumstance 3 . However, this viewpoint of immune privilege has been revised. The CNS derived antigens have been shown to induce immune response. In cancer, the BBB often gets compromised resulting in leakiness 3, 4 .
Recent therapies
Some recent therapies immuno-therapies in brain cancer are listed below. These include (a) To develop strategies that re-educate macrophages to specifically adopt anti-tumor phenotypes in cancer. (b) Enhancing T cell activation by enabling co-stimulation, e.g., through the use of checkpoint inhibitors (c) Dendritic cells vaccines are likewise gaining significant clinical attention as an alternative strategy to stimulate T cell responses and (d) Monocyte/macrophage activation test has been developed as a cellular test of diagnostics and therapy 19 .
DATA AVAILABILITY
The Rembrandt dataset is accessible for conducting clinical translational research using the open access Georgetown Database of Cancer (G-DOC) 20, 21 platform (https://gdoc.georgetown.edu). In addition, the raw and processed genomics and transcriptomics data have also been made available via the public NCBI GEO repository as a super series GSE108476. The MRI medical images for this dataset is available via The Cancer Imaging
